Adiponectin and the steatosis marker Chi3L1 decrease following switch to raltegravir compared to continued PI/NNRTI-based antiretroviral therapy

Medicine & Life Sciences

• Raltegravir Potassium 81%
• Chitinases 79%
• Reverse Transcriptase Inhibitors 66%
• Adiponectin 59%
• HIV 30%
• Metabolic Syndrome 30%
• Fatty Liver 23%
• Biomarkers 21%
• Liver Diseases 18%
• Linear Models 17%
• Protein-Lysine 6-Oxidase 15%
• Tissue Inhibitor of Metalloproteinase-1 13%
• Abdominal Obesity 12%
• Transforming Growth Factors 11%
• Hyaluronic Acid 11%
• Adiposity 11%
• Liver 11%
• CD4 Lymphocyte Count 11%
• Random Allocation 10%
• Nonparametric Statistics 10%
• Peptide Hydrolases 9%
• Therapeutics 9%
• Comorbidity 8%
• Fibrosis 8%
• Enzyme-Linked Immunosorbent Assay 7%
• T-Lymphocytes 6%
• Population 4%

Agriculture & Biology

• adiponectin 77%
• RNA-directed DNA polymerase 65%
• chitinase 58%
• fatty liver 54%
• metabolic syndrome 45%
• therapeutics 42%
• biomarkers 30%
• liver diseases 29%
• comorbidity 17%
• protein-lysine 6-oxidase 17%
• transforming growth factors 14%
• adiposity 14%
• lymphocyte count 13%
• fibrosis 13%
• hyaluronic acid 12%
• metalloproteinases 12%
• obesity 11%
• T-lymphocytes 10%
• enzyme-linked immunosorbent assay 8%
• proteinases 8%
• assays 5%
• tissues 4%
• testing 4%
• cells 3%
• methodology 2%

Chemical Compounds

• Adiponectin 100%
• Raltegravir 94%
• Antiretroviral 78%
• Nonnucleoside Reverse Transcriptase Inhibitor 63%
• Marker 48%
• Biological Marker 29%
• Metabolic 26%
• Hyaluronic Acid 12%
• Plasma 6%